TLDR:
- Life science venture capital firms are experiencing record-low fundraising, potentially impacting startups
- In the first half of the year, VC firms have raised only 15 pools of capital, down from previous years
Biotech VC firms are on track for another year of low fundraising, which may limit the funding available for startups in the coming years. In the first half of 2024, the industry has seen a decrease in the number of funds raised compared to previous years. Many VC firms are struggling post-COVID, grappling with inflated startup valuations and high levels of investment. While the stock market is recovering, the environment is challenging for biotechs. However, there are signs that the pressure is beginning to ease.
